Tratamento com daptomicina em infecção da corrente sanguínea por Enterococcus resistente a vancomicina em paciente com câncer de cólon: desfecho óbito / Treatment with daptomycin for bloodstream infection with vancomycin-resistant Enterococcus in a patient with colon cancer: death outcome
DOI:
https://doi.org/10.34119/bjhrv4n2-189Keywords:
Enterococcus faecium, VRE, VanA, bacteremia, câncer.Abstract
Introdução: Infecção da corrente sanguínea (ICS) por Enterococcus resistente à vancomicina (VRE) é uma complicação grave em pacientes com tumor sólido. Objetivo: Descrever o aspecto clínico e molecular do isolado Enterococcus resistente a vancomicina em paciente com tumor de cólon. Métodos: O isolado de VRE foi identificado e analisado quanto ao perfil antimicrobiano a partir de hemocultura processado por método automatizado vitek®, posteriormente foi submetida para a detecção do gene de resistência à vancomicina, vanA. Resultado: O isolado Enterococcus faecium apresentou resistência à amicacina, eritromicina e vancomicina. O gene VanA foi identificado e iniciado o tratamento com teicoplanina seguida de daptomicina sem sucesso a paciente evoluiu a óbito.
References
Kolonen A, Sinisalo M, Huttunen R, Syrjänen J, Aittoniemi J, Huhtala H, et al. Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study. Infect Dis (Lond). 2017; 49(11-12):799-808. doi: 10.1080/23744235.2017.1347814.
Xie O, Slavin MA, Teh BW, Bajel A, Douglas AP, Worth LJ. Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting. BMC Infect Dis. 2020; 18:20(1):228. doi: 10.1186/s12879-020-04952-5.
Kamboj M, Cohen N, Huang YT et al. Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(3):594-598. doi: 10.1016/j.bbmt.2018.11.008.
Alatorre-Fernández P, Mayoral-Terán C, Velázquez-Acosta C, Franco-Rodríguez C, Flores-Moreno K, Cevallos MÁ, et al. A polyclonal outbreak of bloodstream infections by Enterococcus faecium in patients with hematologic malignancies. Am J Infect Control. 2017; 1:45(3):260-266. doi: 10.1016/j.ajic.2016.10.002.
Teng JC, Lingaratnam SM, Trubiano JA, Thursky KA, Slavin MA, Worth LJ. Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes. Int J Antimicrob Agents. 2016; 47(5):391-6. doi: 10.1016/j.ijantimicag.2016.01.017.
Royo-Cebrecos C, Gudiol C, García J, Tubau F, Laporte J, Ardanuy C, et al. Characteristics, aetiology, antimicrobial resistance and outcomes of bacteraemic cholangitis in patients with solid tumours: A prospective cohort study. J Infect. 2017; 74(2):172-178. doi: 10.1016/j.jinf.2016.10.008.
Krull M, Klare I, Ross B, Trenschel R, Beelen DW, Todt D, et al.Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation. Antimicrob Resist Infect Control. 2016; 22:5-31. doi: 10.1186/s13756-016-0131-6.
Papadimitriou-Olivgeris M, Kolonitsiou F, Karamouzos V. Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012-2016). Eur J ClinMicrobiol Infect Dis. 2020; 2. doi: 10.1007/s10096-019-03803-9.
Cheah AL, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, et al. Estudo caso-caso-controle sobre fatores associados à bacteremia enterocócica resistente à vancomicina e suscetível à vancomicina. BMC Infect Dis. 2014; 14:353.
Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D. Diferentes fatores de risco para bacteremia enterocócica resistente à vancomicina e sensível à vancomicina. Clin Microbiol Infect. 2012; 18(4):388–94.
Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Dominação intestinal e risco de bacteremia em pacientes submetidos a transplante alogênico de células-tronco hematopoiéticas . Clinical Clin Infect Dis 2012; 55:905–914. doi: 10.1093 / cid / cis580.
Amarnani R, Rapose A. Colon cancer and enterococcus bacteremia co-affection: A dangerous alliance. J Infect Public Health. 2017; 10(5):681-684. doi: 10.1016/j.jiph.2016.09.009.
Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resist Updat. 2018; 40:25-39. doi: 10.1016/j.drup.2018.10.002.
Lochan H, Moodley C, Rip D, Bamford C, Hendricks M, Davidson A, Eley B. Emergence of vancomycin-resistant Enterococcus at a tertiary paediatric hospital in South Africa. S Afr Med J. 2016; 9:106(6):39-43. doi: 10.7196/SAMJ.2016.v106i6.10858.
Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007; 54(6):567-71. doi: 10.1016/j.jinf.2006.11.007.
Büyükcam A, Karada? Öncel E, Özsürekçi Y, Cengiz AB, Ku?konmaz B, Sancak B. Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: successful treatment with daptomycin. Arch Argent Pediatr. 2016; 1;114(6):e432-e435. English, Spanish. doi: 10.5546/aap.2016.eng.e432.
Narayanan N, Rai R, Vaidya P, Desai A, Bhowmick T, Weinstein MP. Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia. Ther Adv Infect Dis. 2019; 13;6:2049936119828964. doi: 10.1177/2049936119828964.
Britt NS, Potter EM, Patel N, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clin Infect Dis. 2015; 15;61(6):871-8. doi: 10.1093/cid/civ444. Epub 2015 Jun 10.
Ye JJ, Shie SS, Cheng CW, Yang JH, Huang PY, Wu TS, et al. Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia. J Microbiol Immunol Infect. 2018; 51(6):705-716. doi: 10.1016/j.jmii.2017.08.025.
Shi C, Jin W, Xie Y, Zhou D, Xu S, Li Q, Lin N. Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis. J Glob Antimicrob Resist. 2020; 21:235-245. doi: 10.1016/j.jgar.2019.10.008.
Kim SG, Becattini S, Moody TU, Shliaha PV, Littmann ER, Seok R, et al. Microbiota-derived lantibiotic restores resistance against vancomycin-resistant Enterococcus. Nature. 2019; 572(7771):665-669. doi: 10.1038/s41586-019-1501-z.
Caballero S, Kim S, Carter RA, Leiner IM, Sušac B, Miller L, et al. Cooperating Commensals Restore Colonization Resistance to Vancomycin-Resistant Enterococcus faecium. Cell Host Microbe. 2017; 10;21(5):592-602.e4. doi: 10.1016/j.chom.2017.04.002.
